Active substance
Bupropion
- SFDA 5
- US FDA 72
- Health Canada 11
- US price lines 12
- NHS prices 1
- WHO EML 1
- Safety 16
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| WELLBUTRIN XL 150 EXTENDED RELEASE F.C.TABLET | 150 mg | Prolonged-release film-coated tablet · Oral use | 30 Blister | SAR 65.00 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| WELLBUTRIN XL 300 EXTENDED RELEASE F.C.TABLET | 300 mg | Prolonged-release film-coated tablet · Oral use | 30 Blister | SAR 121.05 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| WELLBUTRIN XL 150 EXTENDED RELEASE F.C.TABLET | 150 mg | Extended-release tablet · Oral use | 30 Blister | SAR 76.50 | Generic · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| WELLBUTRIN XL 300 EXTENDED RELEASE F.C.TABLET | 300 mg | Extended-release tablet · Oral use | 30 Blister | SAR 134.00 | Generic · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| ZYBAN 150MG TABLET | 150 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 248.60 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ALZHEIMER / DEMENTIA; ANXIETY DISORDERS; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER; BIPOLAR II DISORDER; DEPRESSION
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| WELLBUTRIN SR | 100MG; 150MG; 200MG | tablet, extended release · oral | GLAXOSMITHKLINE | Prescription | 4 Oct 1996 |
| BUPROPION HYDROCHLORIDE | 75MG; 100MG | tablet · oral | SENORES PHARMS | Prescription | 7 Feb 2000 |
| BUPROPION HYDROCHLORIDE | 75MG; 100MG | tablet · oral | AUROBINDO PHARMA USA | Prescription | 17 Apr 2000 |
| WELLBUTRIN XL | 150MG; 300MG | tablet, extended release · oral | BAUSCH | Prescription | 28 Aug 2003 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG; 200MG | tablet, extended release · oral | EPIC PHARMA LLC | Prescription | 25 Nov 2003 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG | tablet, extended release · oral | IMPAX LABS | Prescription | 28 Jan 2004 |
| BUPROPION HYDROCHLORIDE | 150MG | tablet, extended release · oral | IMPAX LABS | Prescription | 27 May 2004 |
| BUPROPION HYDROCHLORIDE | 75MG; 100MG | tablet · oral | APOTEX | Prescription | 17 Jan 2006 |
| BUPROPION HYDROCHLORIDE | 150MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 13 Jun 2007 |
| BUPROPION HYDROCHLORIDE | 150MG | tablet, extended release · oral | SANDOZ | Prescription | 12 Mar 2008 |
| APLENZIN | 174MG; 348MG; 522MG | tablet, extended release · oral | BAUSCH | Prescription | 23 Apr 2008 |
| BUPROPION HYDROCHLORIDE | 150MG; 300MG | tablet, extended release · oral | WATSON LABS INC | Prescription | 15 Aug 2008 |
| BUPROPION HYDROCHLORIDE | 150MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 24 Mar 2009 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG; 200MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 24 Mar 2009 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG; 200MG | tablet, extended release · oral | AUROBINDO PHARMA USA | Prescription | 8 Apr 2010 |
| FORFIVO XL | 450MG | tablet, extended release · oral | TWI PHARMS | Prescription | 10 Nov 2011 |
| BUPROPION HYDROCHLORIDE | 150MG; 300MG | tablet, extended release · oral | WOCKHARDT LTD | Prescription | 21 Nov 2012 |
| BUPROPION HYDROCHLORIDE | 300MG; 150MG | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 17 Jan 2014 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG; 200MG | tablet, extended release · oral | PRINSTON INC | Prescription | 26 May 2015 |
| BUPROPION HYDROCHLORIDE | 100MG; 150MG; 200MG | tablet, extended release · oral | SCIEGEN PHARMS | Prescription | 1 Mar 2016 |
| BUPROPION HYDROCHLORIDE | 150MG | tablet, extended release · oral | SCIEGEN PHARMS | Prescription | 17 Aug 2016 |
| BUPROPION HYDROCHLORIDE | 75MG; 100MG | tablet · oral | HERITAGE PHARMA | Prescription | 19 Aug 2016 |
| BUPROPION HYDROCHLORIDE | 150MG; 300MG | tablet, extended release · oral | LUPIN | Prescription | 6 Apr 2017 |
| BUPROPION HYDROCHLORIDE | 150MG; 300MG | tablet, extended release · oral | SCIEGEN PHARMS | Prescription | 12 Apr 2017 |
| BUPROPION HYDROCHLORIDE | 150MG; 300MG | tablet, extended release · oral | ANBISON LAB | Prescription | 30 Jun 2017 |
47 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ODAN BUPROPION SR | 02275074 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | ODAN LABORATORIESLTD |
| ODAN BUPROPION SR | 02275082 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | ODAN LABORATORIESLTD |
| ODAN-BUPROPION XL | 02565838 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | ODAN LABORATORIESLTD |
| ODAN-BUPROPION XL | 02565846 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | ODAN LABORATORIESLTD |
| TARO-BUPROPION XL | 02475804 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TARO-BUPROPION XL | 02475812 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TEVA-BUPROPION XL | 02439654 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-BUPROPION XL | 02439662 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| WELLBUTRIN XL | 02275090 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
| WELLBUTRIN XL | 02275104 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
| ZYBAN | 02238441 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BUPROPION HCL 100 MG TABLET | $0.11295 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL 75 MG TABLET | $0.09282 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL SR 100 MG TABLET | $0.0679 | per EA | 30 Sep 2026 |
| US NADAC | BUPROPION HCL SR 150 MG TABLET | $0.07985 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL SR 150 MG TABLET | $0.25221 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL SR 200 MG TABLET | $0.10362 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL XL 150 MG TABLET | $0.07846 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL XL 300 MG TABLET | $0.10041 | per EA | 23 Sep 2026 |
| US NADAC | BUPROPION HCL XL 450 MG TABLET | $7.99556 | per EA | 23 Sep 2026 |
| US NADAC | WELLBUTRIN SR 100 MG TABLET | $7.06228 | per EA | 23 Sep 2026 |
| US NADAC | WELLBUTRIN SR 150 MG TABLET | $7.51608 | per EA | 23 Sep 2026 |
| US NADAC | WELLBUTRIN SR 200 MG TABLET | $13.97633 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Bupropion 150mg modified-release tablets | £41.76 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.5.2. Medicines for nicotine use disorders · core
Nicotine dependence
Oral > Solid: 150 mg sustained-release (hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 30 Apr 2026 AUVELITY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 CONTRAVE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 APLENZIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 FORFIVO XL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 WELLBUTRIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 WELLBUTRIN SR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2025 WELLBUTRIN XL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 10 Jun 2021 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: No - MHRA 16 Nov 2020 Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs
Cases of serotonin syndrome have been identified in associated with bupropion, especially in overdose or when bupropion is administered with other drugs with a serotonergic effect. - EMA PRAC 1 Oct 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jun 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - US FDA 19 Jul 2019 ZYBAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 10 Jul 2014 PRAC signal: Pancytopenia
Action for MAH: update of the product information: Yes - EMA PRAC 6 Mar 2014 PRAC signal: Pancytopenia
Action for MAH: update of the product information: No
Combinations containing Bupropion
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.